These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27135149)

  • 41. Sirolimus-eluting versus bare-metal stents for the reduction of coronary restenosis: 18-month angiographic results from the GERSHWIN Study.
    Brüggenjürgen B; McBride D; Bode C; Hamm CW; Kuck KH; Willich SN
    Herz; 2007 Dec; 32(8):650-5. PubMed ID: 18060612
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography.
    Cassese S; Byrne RA; Tada T; Pinieck S; Joner M; Ibrahim T; King LA; Fusaro M; Laugwitz KL; Kastrati A
    Heart; 2014 Jan; 100(2):153-9. PubMed ID: 24270744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.
    Hausleiter J; Kastrati A; Mehilli J; Vogeser M; Zohlnhöfer D; Schühlen H; Goos C; Pache J; Dotzer F; Pogatsa-Murray G; Dirschinger J; Heemann U; Schömig A;
    Circulation; 2004 Aug; 110(7):790-5. PubMed ID: 15302787
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rationale and design of the MGuard for acute ST elevation reperfusion MASTER trial.
    Costa JR; Abizaid A; Dudek D; Silber S; Leon MB; Stone GW
    Catheter Cardiovasc Interv; 2013 Aug; 82(2):184-90. PubMed ID: 23008177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Park SJ; Lee JH; Choi SW; Seong IW; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Choi YJ; Kim HS; Lee BK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Park WJ;
    J Am Coll Cardiol; 2011 Mar; 57(11):1264-70. PubMed ID: 21392640
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-in-man randomised comparison of a novel sirolimus-eluting stent with abluminal biodegradable polymer and thin-strut cobalt-chromium alloy: INSPIRON-I trial.
    Ribeiro EE; Campos CM; Ribeiro HB; Lopes AC; Esper RB; Meirelles GX; Perin MA; Abizaid A; Lemos PA
    EuroIntervention; 2014; 9(12):1380-4. PubMed ID: 24755382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
    Sick PB; Brosteanu O; Ulrich M; Thiele H; Niebauer J; Busch I; Schuler G
    Am Heart J; 2005 Apr; 149(4):681-8. PubMed ID: 15990753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han ethnic patients.
    Xu B; Li JJ; Yang YJ; Ma WH; Chen JL; Qiao SB; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2006 Apr; 119(7):533-8. PubMed ID: 16620692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the efficacy and safety of paclitaxel-eluting coroflex please stents and paclitaxel-eluting stents in patients with coronary artery disease: a randomized PIPA trial.
    Kim HS; Park SJ; Park DW; Park SW; Cheong SS; Lee SG; Cho BR; Lee SW; Lee NH; Lee K;
    Catheter Cardiovasc Interv; 2012 Nov; 80(5):799-806. PubMed ID: 22120995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis.
    Xu B; Qian J; Ge J; Wang J; Chen F; Chen J; Wei M; Chen Y; Yang Y; Gao R;
    Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():624-9. PubMed ID: 26775079
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Late catch-up in lumen diameter at five-year angiography in MACE-free patients treated with sirolimus-eluting stents in the Primary Stenting of Totally Occluded Native Coronary Arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II).
    Teeuwen K; Van den Branden BJ; Rahel BM; Laarman GJ; Tijssen JG; Kelder JC; Slagboom T; Ten Berg JM; Suttorp MJ
    EuroIntervention; 2013 Jun; 9(2):212-9. PubMed ID: 23392450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with titanium-nitride-oxide-coated versus everolimus-eluting stents: insights from the BASE-ACS trial.
    Romppanen H; Nammas W; Kervinen K; Mikkelsson J; Pietilä M; Lalmand J; Rivero-Crespo F; Pentikäinen M; Tedjokusumo P; Karjalainen PP
    Minerva Cardioangiol; 2013 Apr; 61(2):201-9. PubMed ID: 23492603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Periprocedural (30-day) risk of myocardial infarction after drug-eluting coronary stent implantation: a meta-analysis comparing cobalt-chromium and stainless steel drug-eluting coronary stents.
    Moreno R; Jimenez-Valero S; Sanchez-Recalde A; Galeote G; Calvo L; Martin-Reyes R; Sabate M; Plaza I; Macaya C; Lopez-Sendon JL
    EuroIntervention; 2011 Mar; 6(8):1003-10. PubMed ID: 21330250
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
    Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schühlen H; Schmitt C; Dirschinger J; Schömig A;
    JAMA; 2005 Jan; 293(2):165-71. PubMed ID: 15644543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.